Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma (MIC-VADS)

5. november 2026 oppdatert av: Centre Hospitalier Sud Francilien

Head and neck squamous cell carcinoma (HNSCC), France's 5th most common cancer (15,000 annual cases), presents significant public health challenges due to high morbidity and functional/aesthetic sequelae from treatments (mutilating surgery, radiotherapy, chemotherapy). Major risk factors, tobacco and alcohol, create a chronic inflammatory environment promoting tumor development. The upper aerodigestive tract microbiome, influenced by these exposures and local alterations (necrosis, bleeding, ulcerations), is emerging as a potential factor in tumor progression, severity biomarker, or therapeutic target, though its exact role (cause or consequence) remains to be elucidated

Objectives:

  • Primary: Compare bacterial microbiome composition between tumor tissue, adjacent healthy mucosa, and pharyngeal secretions
  • Secondary:
  • Correlate microbiome diversity/composition with clinical and epidemiological characteristics
  • Identify microbiome variations by tumor stage, histology, and infiltration
  • Discover diagnostic/prognostic microbial markers
  • Analyze somatic variants (SNP/CNV) via whole-genome sequencing (WGS) and their association with microbiome profiles and clinical parameters

Study Design: Prospective, cross-sectional study with paired design (each patient serves as their own control to minimize genetic variation biases)

Methods:

  • Samples: Tumor, adjacent healthy tissue, and pharyngeal secretions (3 samples/patient)
  • Sequencing: Metagenomic sequencing (complete bacterial genomes) when biomass permits, or targeted 16S rRNA sequencing to identify dominant genera.
  • Pilot study: 20 patients to select the optimal technique and validate feasibility, particularly assessing DNA quantity in these low-biomass environments

Population: Adults with suspected HNSCC scheduled for panendoscopy

Exclusion criteria: Recent antibiotics/corticosteroids (12 weeks), immunosuppression (uncontrolled HIV, active hematologic malignancies, autoimmune diseases on immunosuppressants, organ/stem cell transplants, uncontrolled diabetes), immunomodulatory treatments (3 months), recurrence, pregnancy, non-French speakers, legal guardianship, or lack of social security.

Safety: No additional risks beyond standard panendoscopy.

Expected impact: This approach may pave the way for innovative diagnostic or therapeutic strategies based on microbiome modulation in HNSCC.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

120

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • France
      • Corbeil-Essonnes, France, Frankrike, 91100
        • Centre Hospitalier Sud Francilien
        • Ta kontakt med:
        • Hovedetterforsker:
          • Renato TORRES, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adult patient
  • Consultation in the ENT department for suspected squamous cell carcinoma of the upper aerodigestive tract scheduled for panendoscopy
  • Patient has provided consent to participate in the study and signed an informed consent form

Exclusion Criteria:

  • Antibiotic or corticosteroid therapy within 12 weeks prior to consultation

  • Conditions associated with immunosuppression:

    • Uncontrolled HIV infection (CD4 < 200 cells/µL) (permanent exclusion)
    • Hematologic malignancies currently under treatment or not in complete remission for <2 years
    • Autoimmune diseases under immunosuppressive treatment
    • Solid organ or stem cell transplant recipients (permanent exclusion)
    • Poorly controlled diabetes (HbA1c > 9%)
  • Immunomodulatory treatment within 3 months prior to consultation:

    • Immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4)
    • Biotherapy targeting the immune system (anti-TNF, anti-IL, calcineurin inhibitors, antimetabolites)
    • Recurrent upper aerodigestive tract cancer previously treated with surgery and/or radiochemotherapy
    • Pregnancy (confirmed prior to panendoscopy)
    • Patient who does not speak or understand French
    • Subject under guardianship or curatorship
    • Subject not affiliated with the national health insurance system

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Microbiome in head and neck squamous cell carcinoma Patients

Patients with suspected head and neck squamous cell carcinoma undergoing panendoscopy with additional biopsy sampling of tumor tissue, adjacent healthy mucosa, and pharyngeal secretions for microbiome analysis

Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect:

  • Tumor tissue
  • Adjacent healthy mucosa
  • Pharyngeal secretions

These samples are used for microbiome analysis.

head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention.

Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect:

  • Tumor tissue
  • Adjacent healthy mucosa
  • Pharyngeal secretions

These samples are used for microbiome analysis.

head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
The difference in bacterial composition between the tumor, healthy mucosa, and hypopharyngeal secretions will be assessed
Tidsramme: at day 1
at day 1

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Differences in the tumor microbiome between subgroups defined by tumor stage, histological type, or infiltration, using differentiation tests
Tidsramme: at day 1
at day 1
Differential bacterial genera or strains between tumor, healthy, and pharyngeal microbiomes
Tidsramme: at day 1
at day 1
Correlations between tumor microbiome diversity and composition and clinical/epidemiological data
Tidsramme: at day 1

tumor microbiome diversity (by sequencing) tumor microbiome composition (by sequencing)

at day 1

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Béatrice SEGURENS, Phd, HDR

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

28. februar 2028

Studiet fullført (Antatt)

28. februar 2028

Datoer for studieregistrering

Først innsendt

28. august 2026

Først innsendt som oppfylte QC-kriteriene

7. september 2026

Først lagt ut (Faktiske)

9. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere